Scarica l'app Stockscreener
0.39
0.60%
0.006
Precedente Chiudi:
$0.384
Aprire:
$0.381
Volume 24 ore:
88,112
Relative Volume:
0.61
Capitalizzazione di mercato:
$14.29M
Reddito:
$45.91M
Utile/perdita netta:
$-4.62M
Rapporto P/E:
-2.7817
EPS:
-0.1402
Flusso di cassa netto:
$-21.51M
1 W Prestazione:
+5.09%
1M Prestazione:
-19.35%
6M Prestazione:
-50.50%
1 anno Prestazione:
-74.92%
Intervallo 1D:
$0.375
$0.3974
Intervallo di 1 settimana:
$0.368
$0.414
Portata 52W:
$0.3442
$1.66
Equillium Inc Stock (EQ) Company Profile
Nome
Equillium Inc
Settore
Industria
Telefono
(858) 412-5302
Indirizzo
2223 AVENIDA DE LA PLAYA, LA JOLLA, CA
Confronta EQ con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
EQ
Equillium Inc
|
0.383 | 14.29M | 45.91M | -4.62M | -21.51M | -0.1402 |
|
VRTX
Vertex Pharmaceuticals Inc
|
439.26 | 128.45B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
571.18 | 65.17B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
539.70 | 40.09B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
266.05 | 35.18B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
223.61 | 27.44B | 3.81B | -644.79M | -669.77M | -6.24 |
Equillium Inc Stock (EQ) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-03-28 | Downgrade | Leerink Partners | Outperform → Market Perform |
| 2021-10-29 | Ripresa | Stifel | Buy |
| 2021-09-15 | Iniziato | Cantor Fitzgerald | Overweight |
| 2020-07-14 | Reiterato | H.C. Wainwright | Buy |
| 2020-07-10 | Ripresa | Stifel | Buy |
| 2019-02-22 | Iniziato | SVB Leerink | Outperform |
Mostra tutto
Equillium Inc Borsa (EQ) Ultime notizie
Equillium Announces Multiple Poster Presentations Highlighting EQ504 at the Annual Meeting of The American Association of Immunologists - BioSpace
Renaissance Technologies LLC Sells 59,773 Shares of Equillium, Inc. (NASDAQ:EQ) - Defense World
Equillium stock touches 52-week low at $0.52 amid market challenges - MSN
Head-To-Head Survey: Equillium (NASDAQ:EQ) and KALA BIO (NASDAQ:KALA) - Defense World
Equillium Announces New Aryl Hydrocarbon Receptor Modulator Program EQ504 - BioSpace
Equillium, Inc. Announces New Aryl Hydrocarbon Receptor Modulator Program EQ504 - marketscreener.com
FDA declines itolizumab accelerated approval, says Equillium - The Pharma Letter
Equillium shares fall following FDA feedback By Investing.com - Investing.com India
Equillium shares fall following FDA feedback - Investing.com Australia
Equillium Announces Feedback from the U.S. Food and Drug Adminis - GuruFocus
Equillium (EQ) Faces Setback as FDA Declines Accelerated Approva - GuruFocus
FDA declines Equillium’s itolizumab accelerated approval By Investing.com - Investing.com Canada
Equillium (EQ) Faces FDA Setback for Itolizumab in Graft-versus-Host Disease Treatment | EQ Stock News - GuruFocus
FDA declines Equillium’s itolizumab accelerated approval - Investing.com
Equillium Announces Feedback from the U.S. Food and Drug Administration - Business Wire
Equillium (NASDAQ:EQ) Shares Down 3.7% – Here’s Why - Defense World
Equillium (EQ) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now - Yahoo Finance
Revenues Working Against Equillium, Inc.'s (NASDAQ:EQ) Share Price Following 47% Dive - simplywall.st
Leerink Partnrs Forecasts Equillium FY2029 Earnings - Defense World
Leerink Partners Reaffirms “Market Perform” Rating for Equillium (NASDAQ:EQ) - Defense World
The week in pharma: action, reaction and insight – week to March 28 - The Pharma Letter
Leerink Partnrs Downgrades Equillium (NASDAQ:EQ) to Hold - Defense World
Leerink Partners Downgrades Equillium (LSE:0A4D) - Nasdaq
Equillium stock tumbles on Phase 3 study results By Investing.com - Investing.com India
Equillium stock tumbles on Phase 3 study results - Investing.com
Leerink Partners Downgrades Equillium to Market Perform From Outperform, Adjusts Price Target to $1 From $3 - MarketScreener
Equillium Announces Results of the Phase 3 EQUATOR Study of Itolizumab in First-Line Treatment of Patients with Acute Graft-Versus-Host Disease - BioSpace
Equillium Reports 2024 Financials and Clinical Milestones - TipRanks
Equillium (EQ) Surprises with Smaller Q4 Loss Amid Revenue Dip - GuruFocus
12 Health Care Stocks Moving In Thursday's After-Market Session - Benzinga
Equillium stock hits 52-week low at $0.49 amid market challenges By Investing.com - Investing.com South Africa
Equillium Seeks Accelerated Approval For GVHD Drug Despite Primary Endpoint Miss - insights.citeline.com
Equillium reports mixed results in aGVHD study, seeks FDA fast track By Investing.com - Investing.com South Africa
Equillium pushes for breakthrough status despite missing primary endpoint - Yahoo Finance
Gold Gains Over 1%; TD SYNNEX Shares Plunge After Downbeat Results - Benzinga
Equillium stock hits 52-week low at $0.49 amid market challenges - Investing.com Australia
Equillium fails to improve complete response in GVHD treatment study - Seeking Alpha
Nasdaq Down Over 100 Points; US Initial Jobless Claims Fall - Benzinga
Equillium drug fails main trial goal but shows longer-term promise - The Pharma Letter
Equillium, Inc. Announces Results of the Phase 3 Equator Study of Itolizumab in First-Line Treatment of Patients with Acute Graft-Versus-Host Disease - MarketScreener
Equillium reports mixed results in aGVHD study, seeks FDA fast track - Investing.com
Equillium Reports Phase 3 Results Of Itolizumab For Acute Graft-Versus-Host Disease - MarketScreener
Equillium Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate and Clinical Highlights - Joplin Globe
Breakthrough GVHD Treatment: New Drug Extends Response Duration by 4.7x in Phase 3 Trial - Stock Titan
Equillium (EQ) to Release Quarterly Earnings on Monday - Defense World
Are Medical Stocks Lagging Aveanna Healthcare (AVAH) This Year? - Yahoo Finance
Equillium Stock Price, Quotes and Forecasts - Benzinga
SHAREHOLDER ALERT: Weiss Law Reminds EQ, IMGO, MTCR, and OPNT Shareholders About Its Ongoing Investigations - Marketscreener.com
Equillium stock rallies 26% on itolizumab study data - MSN
Equillium Inc Azioni (EQ) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Equillium Inc Azioni (EQ) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Keyes Jason A | Chief Financial Officer |
Nov 14 '24 |
Sale |
0.70 |
10,000 |
7,000 |
47,720 |
4.19%
0.27%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):